FR2705686B1 - New defective adenovirus and corresponding complementation lines. - Google Patents

New defective adenovirus and corresponding complementation lines.

Info

Publication number
FR2705686B1
FR2705686B1 FR9306482A FR9306482A FR2705686B1 FR 2705686 B1 FR2705686 B1 FR 2705686B1 FR 9306482 A FR9306482 A FR 9306482A FR 9306482 A FR9306482 A FR 9306482A FR 2705686 B1 FR2705686 B1 FR 2705686B1
Authority
FR
France
Prior art keywords
defective adenovirus
new defective
complementation lines
corresponding complementation
corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9306482A
Other languages
French (fr)
Other versions
FR2705686A1 (en
Inventor
Imler Jean-Luc
Methali Majid
Pavirani Andrea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Application filed by Transgene SA filed Critical Transgene SA
Priority to FR9306482A priority Critical patent/FR2705686B1/en
Publication of FR2705686A1 publication Critical patent/FR2705686A1/en
Application granted granted Critical
Publication of FR2705686B1 publication Critical patent/FR2705686B1/en
Priority claimed from AU56251/98A external-priority patent/AU710962B2/en
Priority claimed from US09/409,670 external-priority patent/US6133028A/en
Priority claimed from GR20000402659T external-priority patent/GR3034956T3/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9447589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2705686(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712Cystic fibrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/57IFN-gamma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material
    • C12N2710/10352Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
    • C12N2710/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • C12N2710/10362Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/15Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
FR9306482A 1993-05-28 1993-05-28 New defective adenovirus and corresponding complementation lines. Expired - Lifetime FR2705686B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9306482A FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenovirus and corresponding complementation lines.

Applications Claiming Priority (39)

Application Number Priority Date Filing Date Title
FR9306482A FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenovirus and corresponding complementation lines.
DE1994631372 DE69431372D1 (en) 1993-05-28 1994-05-27 defective adenoviruses
DK98124037T DK0919625T3 (en) 1993-05-28 1994-05-27 defective adenovirus
AT98124039T AT196502T (en) 1993-05-28 1994-05-27 New complementation cell lines for defective adenoviral vectors
ES98124037T ES2182212T3 (en) 1993-05-28 1994-05-27 defective adenoviruses.
DE1994626722 DE69426722D1 (en) 1993-05-28 1994-05-27 adenoviruses defective
JP50031795A JP4226071B2 (en) 1993-05-28 1994-05-27 Defective adenovirus and the corresponding supplemental system
CA 2141212 CA2141212C (en) 1993-05-28 1994-05-27 Defective adenovirus and corresponding complementation lines
US08/379,452 US6040174A (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
AT98124037T AT223968T (en) 1993-05-28 1994-05-27 adenoviruses defective
PCT/FR1994/000624 WO1994028152A1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
DE1994631372 DE69431372T2 (en) 1993-05-28 1994-05-27 defective adenoviruses
EP98124036A EP0919624A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant celllines
DE1998124039 DE919627T1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding Transcomplementing cell lines
SG1996009706A SG55199A1 (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
EP01111931A EP1149916A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant cell lines
EP94917063A EP0652968B1 (en) 1993-05-28 1994-05-27 Defective adenoviruses
DK94917063T DK0652968T3 (en) 1993-05-28 1994-05-27 defective adenovirus
AT94917063T AT199262T (en) 1993-05-28 1994-05-27 adenoviruses defective
ES94917063T ES2155090T3 (en) 1993-05-28 1994-05-27 defective adenoviruses.
DE1994625989 DE69425989D1 (en) 1993-05-28 1994-05-27 New complementation cell lines for defective adenoviral vectors
DE1994626722 DE69426722T2 (en) 1993-05-28 1994-05-27 adenoviruses defective
DK98124039T DK0919627T4 (en) 1993-05-28 1994-05-27 Novel complementation of defective adenovirus
PT94917063T PT652968E (en) 1993-05-28 1994-05-27 Defective adenovirus
EP98124037A EP0919625B1 (en) 1993-05-28 1994-05-27 Defective Adenoviruses
ES98124039T ES2151310T5 (en) 1993-05-28 1994-05-27 New adenoviral vectors defective and corresponding complementing cell lines.
PT98124037T PT919625E (en) 1993-05-28 1994-05-27 Defective adenovirus
PT98124039T PT919627E (en) 1993-05-28 1994-05-27 New cellular lines of complementation for defective adenovary vectors
EP98124039A EP0919627B2 (en) 1993-05-28 1994-05-27 New defective adenovirus and corresponding transcomplementing celllines
EP98124038A EP0919626A3 (en) 1993-05-28 1994-05-27 Defective Adenoviruses and corresponding transcomplementant celllines
AU68503/94A AU6850394A (en) 1993-05-28 1994-05-27 Defective adenoviruses and corresponding complementation lines
DE1994625989 DE69425989T3 (en) 1993-05-28 1994-05-27 New complementation cell lines for defective adenoviral vectors
AU56251/98A AU710962B2 (en) 1993-05-28 1998-02-23 Defective adenoviruses and corresponding complementation lines
US09/409,670 US6133028A (en) 1993-05-28 1999-09-30 Defective adenoviruses and corresponding complementation lines
GR20000402659T GR3034956T3 (en) 1993-05-28 2000-11-30 Defective Adenoviruses and corresponding transcomplementant celllines
US09/725,720 US7005277B2 (en) 1993-05-28 2000-11-30 Defective adenoviruses and corresponding complementation lines
US09/739,007 US7067309B2 (en) 1993-05-28 2000-12-19 Defective adenoviruses and corresponding complementation lines
GR20010400689T GR3035841T3 (en) 1993-05-28 2001-05-09 Defective adenoviruses and corresponding complementation lines.
JP2008248884A JP5410721B2 (en) 1993-05-28 2008-09-26 Defective adenovirus and the corresponding supplemental system

Publications (2)

Publication Number Publication Date
FR2705686A1 FR2705686A1 (en) 1994-12-02
FR2705686B1 true FR2705686B1 (en) 1995-08-18

Family

ID=9447589

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9306482A Expired - Lifetime FR2705686B1 (en) 1993-05-28 1993-05-28 New defective adenovirus and corresponding complementation lines.

Country Status (14)

Country Link
US (3) US6040174A (en)
EP (6) EP0919625B1 (en)
JP (2) JP4226071B2 (en)
AT (3) AT199262T (en)
AU (1) AU6850394A (en)
CA (1) CA2141212C (en)
DE (7) DE69426722D1 (en)
DK (3) DK0919627T4 (en)
ES (3) ES2155090T3 (en)
FR (1) FR2705686B1 (en)
GR (1) GR3035841T3 (en)
PT (3) PT652968E (en)
SG (1) SG55199A1 (en)
WO (1) WO1994028152A1 (en)

Families Citing this family (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2145641C (en) * 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenovirus and corresponding complementation lines.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
CA2162497A1 (en) 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US20020136708A1 (en) 1993-06-24 2002-09-26 Graham Frank L. System for production of helper dependent adenovirus vectors based on use of endonucleases
CN1115414C (en) * 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 Virus carrier used for gene therapy
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
AT272113T (en) * 1994-02-16 2004-08-15 Crucell Holland Bv Melanoma-associated antigens, epitopes thereof and Vaccines against melanoma
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0763103A4 (en) * 1994-04-28 1998-07-15 Univ Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
DE69535178D1 (en) * 1994-06-10 2006-09-28 Genvec Inc Adenoviruses vector systems and cell lines
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
AT246252T (en) 1994-08-16 2003-08-15 Crucell Holland Bv Of adenovirus-derived recombinant vectors for gene therapy
FR2725213B1 (en) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Viral vectors and use in gene therapy
FR2725726B1 (en) 1994-10-17 1997-01-03 Centre Nat Rech Scient Viral vectors and use in gene therapy
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
FR2726285B1 (en) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus devoid of viable contaminating particles, preparation and use
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
EP0797454A4 (en) * 1994-12-12 2001-12-05 Genetic Therapy Inc Improved adenoviral vectors and producer cells
FR2729674B1 (en) * 1995-01-20 1997-04-11 Centre Nat Rech Scient Cells for the production of recombinant adenoviruses
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730411B1 (en) * 1995-02-14 1997-03-28 Centre Nat Rech Scient useful combination drug for transfection and in vivo expression of exogenous
US6251957B1 (en) 1995-02-24 2001-06-26 Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
FR2731710B1 (en) * 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa recombinant viruses expressing lecithin cholesterol acyltransferase, and the use in gene therapy
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant dna virus and a method of manufacturing the same
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
FR2732357B1 (en) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Viral vectors and use for the treatment of hyperproliferative disorders, including restenosis
DE69628744D1 (en) * 1995-04-17 2003-07-24 Univ Texas System Austin Board Adenovirus helper virus system
FR2741891B1 (en) * 1995-06-01 1998-01-09 Centre Nat Rech Scient Cells for the production of recombinant adenoviruses
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5698202A (en) * 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US5985846A (en) * 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP4051416B2 (en) * 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (en) * 1995-06-23 1997-07-25 Centre Nat Rech Scient recombinant adenoviruses, their use for preparation of aav, complementary cell line and pharmaceutical compositions containing them
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
CA2227193A1 (en) 1995-07-17 1997-02-06 Xiaomei Jin P16 expression constructs and their application in cancer therapy
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa New viral vectors and lineage for gene therapy
FR2737221B1 (en) * 1995-07-24 1997-10-17 Transgene Sa New viral vectors for gene therapy
AU727531B2 (en) * 1995-07-25 2000-12-14 Crucell Holland B.V. Methods and means for targeted gene delivery
FR2738575B1 (en) * 1995-09-08 1997-10-10 Centre Nat Rech Scient Cells for the production of recombinant adenoviruses
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6004797A (en) * 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
JP2006075171A (en) * 1995-11-09 2006-03-23 Avigen Inc Accessory functions for use in recombinant aav virion production
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
EP0954591A2 (en) * 1996-05-31 1999-11-10 Baxter International Inc. Mini-adenoviral vector
FR2750433B1 (en) * 1996-07-01 1998-08-14 Rhone Poulenc Rorer Sa Process for the production of recombinant adenoviruses
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US7008776B1 (en) 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
EA003293B1 (en) 1996-12-06 2003-04-24 Авентис Фармасьютикалз Продактс Инк. The polypeptides encoded by the genome of human lipase like gene, compositions containing them and methods of using the compositions
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
FR2761689B1 (en) 1997-04-02 1999-06-25 Transgene Sa adenoviral fiber and modified adenovirus targets
CN1177934C (en) 1997-04-28 2004-12-01 阿文蒂斯药物股份有限公司 Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
WO1998054345A1 (en) * 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
FR2766091A1 (en) 1997-07-18 1999-01-22 Transgene Sa An antitumor composition was immunogenic polypeptide basic cellular localization modified
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6653088B1 (en) 1997-10-24 2003-11-25 Aventis Pharma S.A. Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide
AU752704B2 (en) * 1997-10-24 2002-09-26 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
US6430077B1 (en) 1997-12-12 2002-08-06 Saifun Semiconductors Ltd. Method for regulating read voltage level at the drain of a cell in a symmetric array
DK1049767T3 (en) 1998-01-08 2005-09-19 Aventis Pharma Inc A transgenic rabbit expressing a functional human lipoprotein (a)
BR9906927A (en) 1998-01-14 2001-11-20 Chiron Spa Neisseria meningitidis protein
US6803194B1 (en) 1998-02-13 2004-10-12 Hk Pharmaceuticals, Inc. Use of ribozymes for functionating genes
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AT376591T (en) 1998-05-01 2007-11-15 Novartis Vaccines & Diagnostic Neisseria meningitidis antigenic and assortments
US6225456B1 (en) 1998-05-07 2001-05-01 University Technololy Corporation Ras suppressor SUR-5
US6506889B1 (en) 1998-05-19 2003-01-14 University Technology Corporation Ras suppressor SUR-8 and related compositions and methods
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
JP2002528056A (en) 1998-08-28 2002-09-03 デューク・ユニバーシティー Deficient adenoviruses in IVa2,100K and / or the penultimate protein sequence
DE19856065A1 (en) * 1998-12-04 2000-06-15 Centeon Pharma Gmbh A recombinant adenoviral vector with a limited ability to auto-replication in vivo
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
FR2787465A1 (en) 1998-12-21 2000-06-23 Transgene Sa Process for inactivation of enveloped viruses in virus preparation of non-enveloped viruses
US6441156B1 (en) 1998-12-30 2002-08-27 The United States Of America As Represented By The Department Of Health And Human Services Calcium channel compositions and methods of use thereof
EP1016726A1 (en) * 1998-12-30 2000-07-05 Introgene B.V. Gene therapy to promote angiogenesis
CA2363061A1 (en) * 1999-02-18 2000-08-24 Merck & Co., Inc. Production of helper dependent adenovirus vectors based on use of endonucleases
ES2162551B1 (en) * 1999-04-09 2002-07-01 Univ Madrid Autonoma Procedure for selective replication of adenovirus defective in tumor cells.
US6490775B1 (en) * 1999-04-23 2002-12-10 Veri-Tek Inc. Press operation verification system
EP1228217B1 (en) 1999-04-30 2012-11-21 Novartis Vaccines and Diagnostics S.r.l. Conserved neisserial antigens
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
FR2794771B1 (en) * 1999-06-11 2001-08-10 Aventis Pharma Sa recombinant adenovirus encoding the specific iodine transporter (NIS)
EP1200622A4 (en) * 1999-07-06 2004-12-22 Merck & Co Inc Adenovirus carrying gag gene hiv vaccine
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US6372208B1 (en) 1999-09-28 2002-04-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant virus
FR2799472B1 (en) 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation of recombinant adenoviruses and adenoviral banks
EP1801219B1 (en) 1999-10-29 2015-10-14 GlaxoSmithKline Biologicals S.A. Neisserial antigenic peptides
CN1254719A (en) * 1999-11-19 2000-05-31 钱其军 Defective adenovirus and its building-up method
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
JP2003520248A (en) 2000-01-17 2003-07-02 カイロン エセ.ピー.アー. N. Outer membrane vesicles containing meningitidis serotype b outer membrane protein (OMV) vaccines
EP1290023B1 (en) 2000-03-31 2010-10-27 Aventis Pharmaceuticals Inc. Nuclear factor kb inducing factor
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1167533A1 (en) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
AU2001294562B2 (en) * 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
US6916635B2 (en) * 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
MX357775B (en) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Nucleic acids and proteins from streptococcus groups a b.
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
CN100422210C (en) 2000-12-28 2008-10-01 Wyeth公司 Recombinant protective protein from streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AUPR518501A0 (en) 2001-05-22 2001-06-14 Unisearch Limited Yin yang-1
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US6677156B2 (en) 2001-07-23 2004-01-13 Genvec, Inc. Non-adenoviral gene product-based complementing cells for adenoviral vectors
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
NZ533428A (en) 2001-12-12 2008-03-28 Chiron Srl Immunisation against chlamydia trachomatis
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
CA2478508C (en) * 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
CN100358581C (en) * 2002-04-30 2008-01-02 株式会社载体研究所 Drug- or gene-carrier composition having lowered hemagglutinin activity
CA2484000A1 (en) 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
JP2005532829A (en) * 2002-07-18 2005-11-04 インヴィトロジェン コーポレーション Viral vector containing recombination sites
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US20040052161A1 (en) * 2002-09-17 2004-03-18 Steven Liao Mechanical clock having wireless manipulation and adjustment function
CN1732267A (en) * 2002-10-24 2006-02-08 株式会社载体研究所 Method of transferring gene into t cells
MXPA05005051A (en) 2002-11-12 2006-03-10 Albert B Deisseroth Adenoviral vector vaccine.
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005001082A1 (en) * 2003-06-30 2005-01-06 Dnavec Research Inc. Minus strand rna virus vector carrying gene modified in high mutation region
CN108486086A (en) * 2003-07-02 2018-09-04 维莱尼姆公司 Glucanases, nucleic acids encoding them and methods for making and using them
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
AU2004257935B2 (en) 2003-07-21 2009-11-19 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
EP2397490B1 (en) 2004-07-16 2013-09-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV
JP2007535304A (en) 2003-11-24 2007-12-06 シドニー キンメル キャンサー センター Mucin antigen vaccine
DE602004027538D1 (en) 2003-12-01 2010-07-15 Life Technologies Corp Recombination sites containing nucleic acid molecules and methods of use thereof
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US20050163755A1 (en) * 2003-12-15 2005-07-28 Moy Alan B. Methods and compositions related to 1-caldesmon
WO2005071085A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Process for producing virus vector
US7432057B2 (en) 2004-01-30 2008-10-07 Michigan State University Genetic test for PSE-susceptible turkeys
KR20070001163A (en) * 2004-02-23 2007-01-03 크루셀 홀란드 비.브이. Virus purification methods
ES2407465T3 (en) 2004-03-29 2013-06-12 Galpharma Co., Ltd. New modified galectin 9 protein and use thereof
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
US7604798B2 (en) 2004-07-15 2009-10-20 Northwestern University Methods and compositions for importing nucleic acids into cell nuclei
WO2006013564A2 (en) * 2004-08-04 2006-02-09 S.A.E. Afikim Computerized Dairy Management Systems A method and a system for locating objects in a defined area
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus Purified using ultrafiltration
JP5956709B2 (en) 2005-05-27 2016-07-27 オスペダーレ サン ラファエレ エス.アール.エル Gene vector
US20060286074A1 (en) * 2005-05-31 2006-12-21 Yucheng Tang Methods for immunotherapy of cancer
EP1929021A2 (en) 2005-08-31 2008-06-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
US20090162320A1 (en) * 2005-10-28 2009-06-25 Dnavec Corporation Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein
WO2007059461A2 (en) 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
WO2009030978A2 (en) 2006-06-09 2009-03-12 Novartis Ag Conformers of bacterial adhesins
AU2007276793B2 (en) 2006-07-28 2014-01-16 Sanofi Composition and method for treatment of tumors
US8613925B2 (en) 2006-10-19 2013-12-24 Csl Limited Anti-IL-13Rα1 antibodies and their uses thereof
CA2666679C (en) 2006-10-19 2016-06-07 Merck & Co., Inc. High affinity antibody antagonists of interleukin-13 receptor alpha 1
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp Polynucleotide vector that comprises recombinant cell comprising the vector polypeptide, antibody, composition comprising the polynucleotide, vector, cell or recombinant polypeptide antibody, use of the composition and method for preparing the same composition and prepare a composi
CL2008000249A1 (en) 2007-01-30 2008-05-30 Transgene Sa Use of a nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, a vector or an infectious viral particle which comprises treating a papillomavirus infection caused permanent by at least one papillomavirus
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
ES2337973B8 (en) 2008-05-16 2011-07-21 Proyecto De Biomedicina Cima, S.L. Self-inactivating for the production of high-capacity recombinant adenoviruses. Adenovirus auxiliary
CA2742474C (en) * 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
MX2011004755A (en) 2008-11-05 2011-10-10 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease.
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
JP2012515146A (en) 2009-01-13 2012-07-05 トランジェーヌ、ソシエテ、アノニムTransgene S.A. The use of Saccharomyces cerevisiae mitochondrial nucleic acid fractions for immune stimulation
KR20110116016A (en) 2009-01-20 2011-10-24 트랜스진 에스.에이. Soluble icam-1 as biomarker for prediction of therapeutic response
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
EP2411815B1 (en) 2009-03-24 2015-11-11 Transgene SA Biomarker for monitoring patients
EP2419728B1 (en) 2009-04-17 2014-01-08 Transgene SA Biomarker for monitoring patients
RU2552292C2 (en) 2009-07-10 2015-06-10 Трансжене Са Biomarker for patient selection and related methods
US9393299B2 (en) 2009-08-07 2016-07-19 Transgene S.A. Composition for treating HBV infection
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
AU2010305765B2 (en) 2009-10-15 2015-07-02 Crucell Holland B.V. Method for the purification of adenovirus particles
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
EP2853266B1 (en) 2009-11-09 2018-01-31 Genvec, Inc. Method of propagating monkey adenoviral vectors
KR101820980B1 (en) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Method for the production of Ad26 adenoviral vectors
EP2547362A1 (en) 2010-03-17 2013-01-23 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
TW201221138A (en) 2010-08-23 2012-06-01 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
RU2546873C2 (en) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Non-lipidised variants of neisseria meningitidis orf2086 antigens
EA201390424A1 (en) 2010-09-20 2013-07-30 Круселл Холланд Б.В. Therapeutic vaccination against active tuberculosis
BR112013004582A2 (en) 2010-09-27 2016-09-06 Crucell Holland Bv method for inducing an immune response in a subject against an antigen of a parasite that causes malaria
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
US8911975B2 (en) 2011-02-08 2014-12-16 Mie University Method for producing virus vector for gene transfer
JPWO2012147370A1 (en) * 2011-04-28 2014-07-28 国立大学法人山口大学 Reverse primer for high expression containing terminator sequence and linear dna
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
TWI623618B (en) 2011-07-12 2018-05-11 Transgene Sa Hbv polymerase mutants
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
TW201318637A (en) 2011-09-29 2013-05-16 Transgene Sa Immunotherapy composition and regimen for treating hepatitis C virus infection
EP2764011A2 (en) 2011-10-05 2014-08-13 GenVec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
CN107937440A (en) 2011-10-05 2018-04-20 金维克有限公司 Monkey adenoviral (gorilla) or adenoviral vectors and methods of use
BR112014008167A2 (en) 2011-10-05 2017-04-11 Genvec Inc affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2764014A2 (en) 2011-10-05 2014-08-13 GenVec, Inc. Adenoviral vectors and methods of use
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2809346A1 (en) 2012-02-02 2014-12-10 GenVec, Inc. Adenoviral vector-based malaria vaccine
KR101716557B1 (en) 2012-03-09 2017-03-14 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
US10196429B2 (en) 2012-03-09 2019-02-05 Pfizer Inc. Neisseria meningitidis composition and methods thereof
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EA026620B1 (en) 2012-03-22 2017-04-28 Круселл Холланд Б.В. Vaccine against rsv
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
US9790519B2 (en) 2012-05-29 2017-10-17 Genvec, Inc. Modified serotype 28 adenoviral vectors
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
BR112015000530A2 (en) 2012-07-10 2018-08-28 Transgene Sa mycobacterial antigen vaccine.
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
WO2014107739A1 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Antibodies against pcsk9
ES2685894T3 (en) 2013-03-08 2018-10-15 Pfizer Inc. Immunogenic fusion polypeptides
EP2968613A4 (en) 2013-03-11 2016-10-19 Univ Florida Delivery of card protein as therapy for occular inflammation
SG11201510216RA (en) 2013-06-17 2016-01-28 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
KR20180099912A (en) 2013-09-08 2018-09-05 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
PL3046536T3 (en) 2013-09-19 2019-06-28 Janssen Vaccines & Prevention B.V. Improved adenovirus formulations
JP2017505605A (en) 2014-01-09 2017-02-23 トランスジェン・ソシエテ・アノニムTransgene S.A. Fusions of hetero-oligomeric mycobacterial antigens
WO2016037154A1 (en) 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
EA201790976A1 (en) 2014-11-04 2017-09-29 Янссен Вэксинс Энд Превеншн Б.В. Therapeutic vaccines against hpv16
EP3236998A1 (en) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant metapneumovirus f proteins and their use
JP2018503402A (en) 2015-01-20 2018-02-08 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Chimeric rsv / bPIV3 f recombinant human / bovine parainfluenza virus 3 expressing protein (b / HPIV3) and uses thereof
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
WO2016138160A1 (en) 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
US20180052173A1 (en) 2015-03-18 2018-02-22 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
WO2016166088A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
MX2018002106A (en) 2015-08-20 2018-06-15 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines.
CA3001050A1 (en) 2015-10-06 2017-04-13 Janssen Vaccines & Prevention B.V. Methods for preventing plastic-induced degradation of biologicals
WO2017139392A1 (en) 2016-02-08 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
US20190085032A1 (en) 2016-03-09 2019-03-21 The Unite States of America, as represented by the Secretary, Department of Health and Human Service Recombinant hiv-1 envelope proteins and their use
JP2019514943A (en) 2016-05-02 2019-06-06 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combination
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
EP3518968A2 (en) 2016-10-03 2019-08-07 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
WO2018081318A1 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
AU2018215585A1 (en) 2017-01-31 2019-07-18 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018217935A1 (en) 2017-02-09 2019-07-18 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2018176031A1 (en) 2017-03-24 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
WO2018195527A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2019079240A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant hiv-1 envelope proteins and their use
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
WO2019086450A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
WO2019086461A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
WO2019086456A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
WO2019086466A1 (en) 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
WO2019145310A1 (en) 2018-01-23 2019-08-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8508044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
GB9001766D0 (en) * 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes
US6099831A (en) 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786B1 (en) * 1991-09-27 1995-05-12 Centre Nat Rech Scient
FR2688514B1 (en) * 1992-03-16 1994-12-30 Centre Nat Rech Scient
JPH08501686A (en) * 1992-09-25 1996-02-27 アンステイテユ・ナシヨナル・ド・ラ・サンテ・エ・ド・ラ・ルシエルシユ・メデイカル Adenoviral vectors for the central nervous system, in particular transfer of foreign genes into cells in the brain
EP1321526A3 (en) * 1992-11-18 2003-07-02 Arch Development Corporation Adenovirus-mediated gene transfer to cardiac and vascular smooth muscle
CA2145641C (en) * 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1994023582A1 (en) * 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein
FR2704234B1 (en) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Recombinant viruses, preparation and use in gene therapy.
FR2704556B1 (en) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa recombinant viruses and their use in gene therapy.
CA2162602A1 (en) * 1993-05-10 1994-11-24 James M. Wilson Gene transfer into pancreatic and biliary epithelial cells
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenovirus and corresponding complementation lines.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
CA2162497A1 (en) * 1993-06-10 1994-12-22 Sheila Connelly Adenoviral vectors for treatment of hemophilia
US5543328A (en) 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
DE69535178D1 (en) 1994-06-10 2006-09-28 Genvec Inc Adenoviruses vector systems and cell lines
JP3770333B2 (en) * 1995-03-15 2006-04-26 大日本住友製薬株式会社 Recombinant dna virus and a method of manufacturing the same
JP4051416B2 (en) * 1995-06-15 2008-02-27 クルーセル ホランド ベスローテン フェンノートシャップ Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa New viral vectors and lineage for gene therapy
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors

Also Published As

Publication number Publication date
CA2141212A1 (en) 1994-12-08
EP0919624A2 (en) 1999-06-02
DK0652968T3 (en) 2001-06-11
ES2182212T3 (en) 2003-03-01
EP0919626A3 (en) 1999-08-18
AT196502T (en) 2000-10-15
EP0919627A2 (en) 1999-06-02
EP1149916A2 (en) 2001-10-31
DE69425989T2 (en) 2001-02-22
EP0919627B2 (en) 2007-03-14
AT223968T (en) 2002-09-15
DE69425989T3 (en) 2007-10-18
ES2155090T3 (en) 2001-05-01
EP0652968B1 (en) 2001-02-21
US7005277B2 (en) 2006-02-28
PT919625E (en) 2002-11-29
EP0919627A3 (en) 1999-07-28
EP0919625B1 (en) 2002-09-11
AT199262T (en) 2001-03-15
EP0919626A2 (en) 1999-06-02
PT919627E (en) 2000-12-29
DK0919625T3 (en) 2002-12-30
SG55199A1 (en) 1998-12-21
DE69431372D1 (en) 2002-10-17
ES2151310T5 (en) 2007-10-16
GR3035841T3 (en) 2001-08-31
DK0919627T4 (en) 2007-06-25
WO1994028152A1 (en) 1994-12-08
JPH07509616A (en) 1995-10-26
DE69431372T2 (en) 2003-07-31
FR2705686A1 (en) 1994-12-02
JP4226071B2 (en) 2009-02-18
PT652968E (en) 2001-07-31
ES2151310T3 (en) 2000-12-16
US20010049136A1 (en) 2001-12-06
CA2141212C (en) 2007-04-17
EP1149916A3 (en) 2007-08-29
US6040174A (en) 2000-03-21
DE69425989D1 (en) 2000-10-26
JP5410721B2 (en) 2014-02-05
DE69426722T2 (en) 2001-09-20
EP0919627B1 (en) 2000-09-20
AU6850394A (en) 1994-12-20
DK0919627T3 (en) 2001-01-22
DE69426722D1 (en) 2001-03-29
EP0919625A2 (en) 1999-06-02
US20030170885A1 (en) 2003-09-11
EP0919625A3 (en) 1999-08-18
JP2009050267A (en) 2009-03-12
EP0919624A3 (en) 1999-08-18
EP0652968A1 (en) 1995-05-17
US7067309B2 (en) 2006-06-27
DE919627T1 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
DK0868530T3 (en) The cascade-nucleinsyreamplificeringsreaktion
DK1367057T3 (en) Epothilones E and F
DK0938661T3 (en) analyzer
DK0689428T3 (en) Increased cirkulationseffektorpræparat and method
DK1267013T3 (en) Laminatgulvstætning
DK0683632T3 (en) Törpulvertilförselssystem
DK0697825T3 (en) Skosålskomponent
DK0691013T3 (en) Afbenyttelsesafregningssystem
DK0737307T3 (en) Væskegennemstrømningscytometer
DK0630617T3 (en) Aspirationskateterindretning
DK0730740T3 (en) Kinasereceptoraktiveringsassay
DK0719278T3 (en) Androstenonderivat
FI99070B (en) Rack
DK0938544T3 (en) Cell / vævsdyrkningsindretning and method
DK0653439T3 (en) Stabilized oligonucleotides and their application
DK0699077T3 (en) Immunogele HIV-complexes
DK0728207T3 (en) Telomeraseaktivitetsassays
NO901026D0 (en) Telesproganalysator and method.
DK0635558T3 (en) Gasoliesammensætning
DK0790258T3 (en) Photo-cross-linked polymers
NO963175D0 (en) Analytic and measuring method
DK0804122T3 (en) Cervixvævsprøveudtagningsindretning
DK0659344T3 (en) Tørgærsblanding
DK23293D0 (en) Boejeligt dilatationselement
DK0800519T3 (en) Steroidreceptormodulatorforbindelser and Methods